Vaginal estrogen and association with dementia

Vaginal estrogen and association with dementia: A nationwide population-based study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Vaginal estrogen and association with dementia : A nationwide population-based study. / Pourhadi, Nelsan; Mørch, Lina S.; Holm, Ellen A.; Torp-Pedersen, Christian T.; Meaidi, Amani.

In: Alzheimer's and Dementia, Vol. 18, No. 4, 2022, p. 625-634.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pourhadi, N, Mørch, LS, Holm, EA, Torp-Pedersen, CT & Meaidi, A 2022, 'Vaginal estrogen and association with dementia: A nationwide population-based study', Alzheimer's and Dementia, vol. 18, no. 4, pp. 625-634. https://doi.org/10.1002/alz.12417

APA

Pourhadi, N., Mørch, L. S., Holm, E. A., Torp-Pedersen, C. T., & Meaidi, A. (2022). Vaginal estrogen and association with dementia: A nationwide population-based study. Alzheimer's and Dementia, 18(4), 625-634. https://doi.org/10.1002/alz.12417

Vancouver

Pourhadi N, Mørch LS, Holm EA, Torp-Pedersen CT, Meaidi A. Vaginal estrogen and association with dementia: A nationwide population-based study. Alzheimer's and Dementia. 2022;18(4):625-634. https://doi.org/10.1002/alz.12417

Author

Pourhadi, Nelsan ; Mørch, Lina S. ; Holm, Ellen A. ; Torp-Pedersen, Christian T. ; Meaidi, Amani. / Vaginal estrogen and association with dementia : A nationwide population-based study. In: Alzheimer's and Dementia. 2022 ; Vol. 18, No. 4. pp. 625-634.

Bibtex

@article{7c67a6ad1652438e8df713f7c6b1f10b,

title = "Vaginal estrogen and association with dementia: A nationwide population-based study",

abstract = "Introduction: Use of systemic hormone therapy has been positively associated with development of dementia. Little is known about the dose-dependent effect of vaginal estradiol on dementia risk. Methods: We assessed associations between cumulative dose of vaginal estradiol tablets and dementia in a case-control study nested in a nationwide Danish cohort of women aged 50 to 60 years at study initiation, who did not use systemic hormone therapy. Each case was age-matched to 10 female controls. Results: A total of 4574 dementia cases were matched to 45,740 controls. Cumulative use of vaginal estradiol tablets was not associated with all-cause dementia; adjusted hazard ratio 1.02 (95% confidence interval [CI] 0.89–1.18) for low dose (< 750 mcg), 1.07 (0.94–1.21) for medium dose (750–2000 mcg), and 0.93 (0.84–1.03) for high dose (> 2000 mcg). Similarly, Alzheimer's disease (AD) only was not associated with vaginal estradiol. Discussion: Exposure to vaginal estradiol tablets was not associated with all-cause dementia or AD only.",

keywords = "Alzheimer's disease, dementia, hormone therapy, nationwide study, pharmacoepidemiology, register study, risk factor, vaginal estrogen",

author = "Nelsan Pourhadi and M{\o}rch, {Lina S.} and Holm, {Ellen A.} and Torp-Pedersen, {Christian T.} and Amani Meaidi",

note = "Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association",

year = "2022",

doi = "10.1002/alz.12417",

language = "English",

volume = "18",

pages = "625--634",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "4",

}

RIS

TY - JOUR

T1 - Vaginal estrogen and association with dementia

T2 - A nationwide population-based study

AU - Pourhadi, Nelsan

AU - Mørch, Lina S.

AU - Holm, Ellen A.

AU - Torp-Pedersen, Christian T.

AU - Meaidi, Amani

PY - 2022

Y1 - 2022

N2 - Introduction: Use of systemic hormone therapy has been positively associated with development of dementia. Little is known about the dose-dependent effect of vaginal estradiol on dementia risk. Methods: We assessed associations between cumulative dose of vaginal estradiol tablets and dementia in a case-control study nested in a nationwide Danish cohort of women aged 50 to 60 years at study initiation, who did not use systemic hormone therapy. Each case was age-matched to 10 female controls. Results: A total of 4574 dementia cases were matched to 45,740 controls. Cumulative use of vaginal estradiol tablets was not associated with all-cause dementia; adjusted hazard ratio 1.02 (95% confidence interval [CI] 0.89–1.18) for low dose (< 750 mcg), 1.07 (0.94–1.21) for medium dose (750–2000 mcg), and 0.93 (0.84–1.03) for high dose (> 2000 mcg). Similarly, Alzheimer's disease (AD) only was not associated with vaginal estradiol. Discussion: Exposure to vaginal estradiol tablets was not associated with all-cause dementia or AD only.

AB - Introduction: Use of systemic hormone therapy has been positively associated with development of dementia. Little is known about the dose-dependent effect of vaginal estradiol on dementia risk. Methods: We assessed associations between cumulative dose of vaginal estradiol tablets and dementia in a case-control study nested in a nationwide Danish cohort of women aged 50 to 60 years at study initiation, who did not use systemic hormone therapy. Each case was age-matched to 10 female controls. Results: A total of 4574 dementia cases were matched to 45,740 controls. Cumulative use of vaginal estradiol tablets was not associated with all-cause dementia; adjusted hazard ratio 1.02 (95% confidence interval [CI] 0.89–1.18) for low dose (< 750 mcg), 1.07 (0.94–1.21) for medium dose (750–2000 mcg), and 0.93 (0.84–1.03) for high dose (> 2000 mcg). Similarly, Alzheimer's disease (AD) only was not associated with vaginal estradiol. Discussion: Exposure to vaginal estradiol tablets was not associated with all-cause dementia or AD only.

KW - Alzheimer's disease

KW - dementia

KW - hormone therapy

KW - nationwide study

KW - pharmacoepidemiology

KW - register study

KW - risk factor

KW - vaginal estrogen

U2 - 10.1002/alz.12417

DO - 10.1002/alz.12417

M3 - Journal article

C2 - 34322991

AN - SCOPUS:85111381072

VL - 18

SP - 625

EP - 634

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5260

IS - 4

ER -

ID: 275942891

Forskning